Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
arca was pulled. back to 14 mms on ih site
Looks like 2 new MMs. ARCA and STXG. The former trades NYSE issues electronically. HMM.
Investing is all about timing. Duh. You only have to be right once just. See Thomas Edison. The issue of approval should be resolved, one wat or the other, before the end of the year. You gotta be in it to win it. Risk/Reward here tilts toward reward as the stock remains a disappointment.......until it's not. Money Talks and Bullshit Walks.
With the latest result indicating an over 80% Survival rate after 5 years as opposed to under 50% without Multikine, it appears that approval is a foregone conclusion after the confirmatory study succeeds. Stock remains a strong buy.
Will nwbo be presenting at the ESMO Convention which started today in Barcelona.? TIA
Oh ye of little faith. It will be interesting to see what they say at the conference in Barcelona tomorrow.
Most reads 1 million on IH #1.
Hi Sleuth. When you get a chance can you get the latest Court memo regarding the stay in District Court. Since the Accord case is now closed, it would appear the stay should or will be vacated soon. TIA.
Highest volume in over 1 month. Hmmm
Wake up little Susie. Wake up.
There are two Price/Earnings ratios. The P/E cited here has been the trailing P/E ratio which is based upon the past years revenue stream. The forward P/E is a better indicator for this stock as most here can anticipate a big increase in revenue compared to the last fiscal year of $56M. If projections about Vyvanse are correct, and 3 more ANDAs are launched, a $100M fiscal 2025 seems possible. My long winded point is that the current P/E cited is way too conservative.
CVM to present new data for Multikine at the European Society for Medial Oncology 2024 Medical Oncology Congress Saturday 9/13/24 in Barcelona Spain.
Expect the stay in Purdue v. Elite to be lifted in the near future. While I agree with Jour that is is not a material event, the lift of the stat will be indicated on the Curt document and available for our resident sleuth who is also doing excellent work on behalf of this board of shareholders and naysayers.
Great due diligence. You and Nas are the best source of good and helpful data sine the late great N2K. Keep up the good work.
All quiet on the Western front.
Go to settings. Hit ignore list and and click on he party you ignored. You will get their latest posts. But why waste time with bad vibes?
My guess is that the stay will be lifted and either a discovery order will be issued or Purdue will file a motion to dismiss. I expect that Purdue will appeal the final Judgment which may cause the Court to continue the stay in our case. In any event very good news indeed albeit the journey will not be short.
The broken record won't be back until October 1.
The filing for an ANDA for Concerta looms as the third blockbuster and, as Jour points out, may indeed produce more revenue than Vyvanse given less competitors. Apparently this filing is awaiting the successful completion of BE study which Hakim has indicated is underway some time ago.
I am looking forward to a possible filing before the end of the year with the new revenue baby due 10 months thereafter. If this company ends up selling Adderall, Vyvanse and Concerta, it may indeed deserve a market cap in excess of a billion bucks or more.
Excellent information. Elite seems to meet many of the criteria for a buyout.
There are now 13 MMs trading this stock.
Ditto. I can't container my emotions on this one.
Looks like a Freudian Typo. Staristics: Definition a Corp that produces revenue that is out of this world.
Can you explain why the company name Vivos, which can be confused with Vivos Therapeutics, does not change its name to RadioGel? As I am a newbie, please excuse my ignorance.
Do you have a guess on what a fair market cap would be if RadioGel is approved? Current 56 million cap, before the offering is completed, seems low. I think $500m, or $1.30, seems about right for the coming year. Please go easy on me.
Many of the "works on Wall Street" guys are critical of OTC stocks as many brokerages refuse to trade them since they are not marginable and may not be shorted (market makers accepted). That being said, investors here should not be deterred from holding a nice position in a stock which will eventually be on Nasdaq or be a part of a NYSE stock which took them over. We are doing just fine without the smart money guys who don't appreciate that YTD Elite has outpaced even the great Nividia results.
It is amazing that investors don't realize that when CVM reveals that they have enrolled the 212 patients to do the confirmatory study, this stock will move higher. If the study shows good preliminary results, they may be fast tracked. Watch for volume surge in the near future. As for the timeline, if they are able to enroll 53 patients a month on average, they would reach the quota on September 8. I'm locked and loaded here.
Took a nice opening position here. Assuming a fda go ahead by mid September, I am still unsure of the market potential for both radiogel and isopet. Another unknown is the status of the $60M stock offering.
It was good to see that the CEO with a massive stock position still opted to buy cheap shares which is a positive. With a current market cap of only $56M, this is a strong temping buy. If one conservatively believes this company could be worth $500M market cap or more, this could be a 10 bagger. Stock being held down by the going concern caveat, but if they get the needed financing, this can be a big winner. But the days grow short when you reach September.
God Bless and God save the King. Please keep your word this time.
I see we added another market maker: the notorious ASCM. Now a lucky 13.
Obviously the key here will be the success of the upcoming confirmatory trial for those with head and neck cancer that has not spread to the lymph nodes. That group is more likely to survive this pernicious disease that had claimed the lives of loved ones all over the earth. God Bless them and pray that they succeed.
Great post in summarizing the conference call which was truly forward looking. I cannot think of any post that is more deserving of a stickie! I have printed it out to send to those who deserve the opportunity to be a shareholder in what will be a great company to have in your portfolio.
For someone to have to declare as an insider , they would have to own 170 million shares. If this stock is being accumulated for a takeover, it would not be unusual for them to grab 10 % before making the offer. If you did your homework and knew Vyvanse approval was near, you might try to lock up 10% of the voting rights. Just sayin.
I expect Vyvanse approval on November 20. Then we can all celebrate Thanksgiving literally and happily. Still time to gobble them up.
We don't need no education, we don't need no ground control, All I want is..........
Good call on the Methotrexate launch. I took a nice opening position on your favorite pet company. When your hot your hot.
Next launch ,my guess, is the Tylenol with Codeine, around the last week of September. And the days dwindle down to a precious few, September, November, and these few precious days I'll spend with you all, at the Hotel in Las Vegas.
Patience is the buy word.
Agree new investors likely with recent positive articles from Reddit, Investing.com and Walk the Street. I expect long time followers at Seeking Alpha also to chime in soon. Hopefully positive momentum will continue with new launches news releases. Expect daily volume to start to average at least 2 million per day.
With the need to purchase API for the expected 5 ANDA launches to be completed within the next 12 months, as well as increased spending on R&D for BE studies and the soon to be opened storage facility, I expect that Elite will resort to some bank loans for the extra needed funds. While revenue has increased, the launch to cut into the additional $6B plus market will be challenging as the company enters a new explosive growth era. Luckily, as alluded to by NH, Elite can now resort to bank funding to enhance its money needs. As those who watch Shark Tank know, the smart money always will invest to fund real purchase orders.
Indeed as the new article ( good find BTW) suggests, Elite is ready for a breakout. I am confident the faithful will enjoy the ride, albeit a bit bumpy until it reaches orbit.
Thank you HAL.
Can't wait to read Monday's news.